Aeterna Zentaris Inc
Change company Symbol lookup
Select an option...
AEZS Aeterna Zentaris Inc
SPUU.NV Direxion Daily S&P 500 Bull 2X Shares
NEOV NeoVolta Inc
SYBX Synlogic Inc
FIISO Financial Institutions Inc
KA Kineta Inc
TCS Container Store Group Inc
MLGO MicroAlgo Inc
INDI indie Semiconductor Inc
JCI Johnson Controls International PLC

Health Care : Biotechnology | Small Cap Growth
Based in Canada
Company profile

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.

Closing Price
Day's Change
-0.11 (-4.21%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

MSCI Inc. Stock Falls Friday, Underperforms Market

5:11 pm ET May 19, 2023 (MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of MSCI Inc. (MSCI) slipped 0.51% to $469.84 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.14% to 4,191.98 and Dow Jones Industrial Average falling 0.33% to 33,426.63.

The stock's fall snapped a two-day winning streak.

MSCI Inc. closed $102.66 short of its 52-week high ($572.50), which the company achieved on February 2nd.

The stock underperformed when compared to some of its competitors Friday, as JPMorgan Chase & Co. (JPM) fell 0.23% to $139.18, Charles Schwab Corp. (SCHW) fell 0.15% to $51.67, and BlackRock Inc. (BLK) fell 0.39% to $666.70.

Trading volume (345,484) remained 168,888 below its 50-day average volume of 514,372.

Data source: Dow Jones Market Data, FactSet. Data compiled May 19, 2023.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

May 19, 2023 17:11 ET (21:11 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.